Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Incorporation of orthophosphate-32P into erythrocyte phospholipids in normal subjects and in patients with hereditary spherocytosis
Claude F. Reed
Claude F. Reed
Published December 1, 1968
Citation Information: J Clin Invest. 1968;47(12):2630-2638. https://doi.org/10.1172/JCI105946.
View: Text | PDF
Research Article

Incorporation of orthophosphate-32P into erythrocyte phospholipids in normal subjects and in patients with hereditary spherocytosis

  • Text
  • PDF
Abstract

The in vitro incorporation of inorganic 32P into erythrocyte phospholipids has been studied in normal subjects and in splenectomized patients with hereditary spherocytosis (HS). Phosphatidic acid (PA) was the only lipid measurably labeled in both kinds of cells. The actual turnover rate of PA phosphate was determined by simultaneously isolating inorganic phosphate (Pi) and adenosine triphosphate (ATP) and determining their specific activities. This turnover is very small: 1.3 μmoles P/liter of erythrocytes per hr in normal cells and 4.0 μmoles P in HS erythrocytes when either ATP or cellular Pi is considered the immediate precursor. This value represents less than 0.1% of the total membrane lipid phosphate. Incorporation of added 32Pi into the other phosphatides, including phosphatidyl serine, was essentially zero in both kinds of cells.

Authors

Claude F. Reed

×

Full Text PDF

Download PDF (1.44 MB)

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts